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Abstract 
 
Antibody effector functions other than neutralization depend on interactions with soluble 
and cellular components of the immune system. Antigen recognition is usually 
oligoclonal, with the different clones of antibodies belonging to different classes, 
subclasses, glycoforms and having different affinities and epitope specificities. Thus, 
composition of immune complexes determines biological effects mainly via interactions 
with FcR and complement proteins. Antibodies are capable of triggering any of the three 
pathways of complement activation and antigen recognition of complex antigens often 
results in the activation of more than one pathway. These events can be tracked in a 
multiplex format using antigen microarrays, where complement products bind to 
elements of the microarray. By controlling cation concentrations and detecting various 
complement components (C1q, C4, C3) contribution of the different pathways can be 
identified. Parallel measurement of antibodies and complement proteins provides a novel 
way of looking at interactions between antigen and antibodies. We propose the use of 
immune complex signatures, composite depictions of antibody and complement content 
of immune complexes characterizing healthy and diseased populations. Normalized 
interquartile ranges of antibody binding (IgM, IgG) and complement deposition (C4, C3) 
are projected onto radar charts to produce patterns that can distinguish normal and altered 
immune responses. 
The comprehensive interaction studies of serum antibodies and complement with arrays 
of antigens can generate profiles for a better understanding of disease mechanism.  
1 Antibodies, complement and arrayed antigen 
The complement system participates in wide ranging biological phenomena, starting from 
regulation of organogenesis and regeneration through mediation of inflammation to 
promoting opsonic phagocytosis to modulation of adaptive immunity. This variability is 
partly due to the fact that the system has about 30 components and also due to the 
presence of a variety of receptors on different cell types. While complement activation 
usually implies the triggering of one of the pathways which then proceeds to the 
formation of the membrane attack complex, it is important to note that the cascade of 
enzymatic cleavage events can be blocked at several points by natural inhibitory and 
regulatory molecules, producing a different outcome. Antibodies are usually associated 
with classical pathway, where antigen-bound IgM or IgG provides binding sites for C1q, 
leading to activation of the associated serine proteases C1r and C1s. However, it is 
important to note that not only classical but also the lectin and alternative pathways can 
be triggered by antibodies bound to their target [1]. Accordingly, IgG molecules have 
sites associated with the triggering of these pathways, as shown in Figure 1. 
Antigens coupled to a solid surface can serve as targets of antibodies, as long as 
important conformational epitopes are not lost due to structural changes induced by 
adsorption, covalent linkage, dehydration or other technical factors associated with 
production. In our experience nitrocellulose is a universal surface that can bind all kinds 
of macromolecules, such as proteins, lipids, nucleic acids and their various complexes. 
Random adsorption to the nitrocellulose sponge allows access to any part of the antigen. 
While the use of peptides instead of whole proteins has certain advantages [2] in antibody 
profiling, only native antigens reflect in vivo immune complex formation. Multiple 
epitopes recognized within the same antigen, determined by the diversity of the immune 
response, promote complement activation due to the increased density of antibodies. 
Otherwise, epitope density on the microarray can be controlled by adjusting 
concentration of the antigen solution used for array printing. At a given epitope density 
antibodies with higher affinity will be more potent complement activators as the time 
spent in antigen-bound form will be longer. Therefore, on part of the antigen, quality and 
epitope density, on part of the serum, antibody diversity and affinity is reflected by 
complement activation. 
Human IgG subclasses differ greatly in their effector potential, both in FcR and 
complement mediated events. Switching to these isotypes is determined by the nature of 
the antigen (and adjuvant), and while dominance of certain isotypes can characterize 
immunity, usually one can expect different IgG subclasses to be bound to arrayed 
antigens. The ratio of these subclasses can determine the extent of complement 
activation. 
Another important property of IgG molecules is the composition of the N-linked 
carbohydrate moiety: different glycoforms possess different effector functions, again both 
by FcR [3,4] and complement [5] mediated processes. Terminal fucose, mannose and N-
acetyl glucosamine molecules present in certain glycoforms are preferred sites for MBL. 
Lectin pathway-initiated complement activation has been shown to contribute to antibody 
mediated effector functions in disease [6]. In summary, the nature and extent of 
complement activation induced by a certain antigen in a given serum sample integrates a 
wealth of information about the bound antibodies. 
The pathway that leads to C3 deposition can be identified by looking at complement 
proteins on the antigen array under three different conditions: in the presence of both 
Ca
2+
 and Mg
2+
 ions, in the presence of Mg
2+
 ions with Ca
2+
 ions chelated by EGTA, and 
in the absence of cations, all being chelated by EDTA (Fig. 2). The presence of C1q 
indicates involvement of the classical pathway; its binding is not affected by cation 
concentrations. C4 deposition results either by classical or lectin pathway initiated events, 
both being dependent on Ca
2+
 ions; C4 in the absence of C1q therefore indicates lectin 
pathway activation. Finally, C3 is generated by all three pathways but only the alternative 
pathway is active in the absence of Ca
2+
 ions. Figure 2B demonstrates that a bacterial 
superantigen, fusion protein LA, triggers both the classical and the alternative pathway by 
capturing IgG from the tested serum. 
 
2 Interpreting complement activation as a function of antibody binding 
Allowing serum proteins to react with arrayed antigens under conditions that support 
complement activation, we have wide choice of serum proteins for measurement. As for 
immunoglobulins, except for IgD, all classes and subclasses have been shown to be 
detectable on antigen arrays [7]. Therefore the choice mainly depends on the purpose of 
the study; we have mostly used IgG detection for the assessment of vaccination effects 
and to monitor autoreactivity. Concerning complement proteins, we have successfully 
detected C1q, C1INH, C4, C3 and C5b-9 neoantigen. Since C3 plays a central role in 
complement activation and its density correlates with C5 convertase activity [8], its 
measurement provides a good overall picture about complement activation events. 
Though it is actually not C3 but its fragments (C3b, iC3b, C3dg) that are bound to the 
array, from here on we neglect this fact and continue to call array-bound forms C3 in 
general. It is important to note that parallel detection of immunoglobulins and 
complement proteins has certain technical tricks, which were recently described [9]. 
While our group focuses on complement function, other approaches of interpreting 
combined immunological binding events are also being developed [10]. 
2.1 2D profiles – comparing antigens 
The ability of antigens to capture immunoglobulins and complement proteins (Fig. 3A) 
spans a very wide range starting from non-detectable to very high values. Binding of 
immunoglobulins can be explained by the presence of natural antibodies and prior 
exposure to the antigen. This latter category, the “reactome”, includes environmental 
antigens, accidental or intentional inoculation of pathogens and self antigens. 
Complement activation on the antigen is more difficult to predict, being influenced by 
non-immunoglobulin and immunoglobulin factors as well. The physico-chemical nature 
of the antigen determines the binding of recognition molecules such as pentraxins, 
lectins, and of complement regulatory proteins such as factor H or C4BP. These 
molecules can up- or downregulate the complement cascade, influencing the amount of 
different complement products generated. Thus, the ratio of proteins along the C4-C3-
C5b-9 axis can vary as a function of these proteins, irrespective of the bound 
immunoglobulins. Complement activating ability of immunoglobulins was discussed in 
the previous section. 
The ideal concentration of antigens for arraying has been shown to be between 0.1-1.0 
mg/ml. In order to compare two different antigens on a molar basis, equimolar solutions 
should be printed on the antigen arrays. While this is usually not the case, the use of 
different dilutions allows a rough qualitative comparison to be made, especially for 
protein antigens that have similar molecular weights. Figure 3B shows the relative 
composition of immune complexes formed on 5 different antigens. This kind of 
comparison is very precise, as protein interactions take place on the very same array 
under identical conditions. On the other hand, special reagents may be required to 
confirm that identical – ideally known – amounts of the antigens are present on the array 
surface. This is achieved by the use of peptide tags and tag specific antibodies in the case 
of recombinant antigens [11]. 
2.2 2D profiles – comparing serum samples 
When the comparison of reactivity of different serum samples is the goal, reactions take 
place in different reaction chambers (Fig. 3A). This necessitates the use of quality control 
and normalization procedures that compensate either for technical or for biological 
variation. On the technical side, array printing can introduce variability in the amount of 
antigen printed and in antigen quality. On the biological side, absolute concentrations of 
immunoglobulins and complement proteins and functional activity of complement system 
shows individual variability, due to genetic and environmental factors. The measurement 
of these biological variations is often not the purpose of antigen array experiments, rather 
these factors should be compensated for. As an example, normalization for total 
immunoglobulin M levels has been proposed as a means to render IgM binding results 
comparable [12]. Serum concentrations of complement C3 and C4 vary in the range of 
1.0–1.85 g/l and 0.2–0.45 g/l, respectively; in a similar manner, normal complement 
activity, as assessed by CH50 measurement, also spans a log2 range. Our approach is to 
determine the relative complement activating properties of antigen-bound antibodies, 
therefore we normalize results to complement deposition on obligate complement 
activating substances [9]. This approach allowed the distinction between antibody 
profiles induced by different adjuvants [13] and to monitor the progressive qualitative 
change of antinuclear antibodies in a murine model of lupus erythematosus [14]. 
2.3 2D profiles – plotting antigens and serum profiles  
Alterations in the reactivity pattern of serum antibodies reflect changes in the immune 
system. Antibody profiling has been used to characterize these changes both with the 
purpose of identifying markers of disease and of generating multiparameter algorhytms 
for defining disease status. Visualizing these changes in two dimensions can provide an 
interesting and informative functional view of humoral immunity; an example is shown 
in figure 3B. 
 
3 Description of immune complex content on a population level: immune complex 
signatures 
Experimental data, in agreement with the expectable correlations [15] suggested that it is 
mostly IgM and IgG that determines complement depositions to self antigens. Detection 
of these two classes of immunoglobulins seems inevitable in order to interpret effector 
functions. On the complement side, alternative pathway and its amplification loop were 
identified as important contributors to disease pathogenesis. Thus, the measurement of 
both C4 and C3 is required to assess relative contribution of alternative and the other two 
pathways. Current microarray scanning technology allows the simultaneous detection at 
four different wavelengths, so technically concurrent measurement of IgM, IgG, C4 and 
C3 is feasible. Another concern could be the interference of the detecting secondary 
antibodies with each other and thereby the skewing of signals by more abundant proteins. 
Our pilot experiments indicated that this was not the case (data not published) so we set 
out to measure the four proteins in parallel. 
Measurement of the binding of four different proteins to an antigen raises the issue of 
how to present data in a way that is both simple and informative. Radar charts – also 
called cobweb charts or star plots - are suitable for displaying multivariate data in two 
dimensions. They consist of a sequence of spokes or axes that start from the same point 
and represent one variable each. Data points belonging to one observation are plotted on 
each axis and are then connected by a line. The resulting star-like plot can be used for the 
qualitative characterization of an observation. Typically many observations are plotted on 
a single chart so that observations with similar or dissimilar star shapes can be visualized. 
We adapted this method for displaying data ranges. Observations are interquartile ranges 
of values expressed as percentage of maximal observed values. Observations for 
individual samples are star shaped lines, whereas observations for populations are star 
shaped areas. These areas can be displayed on separate charts or as an overlay (fig 4). 
IgM and IgG are displayed on opposite axes to represent natural, low affinity responses 
in contrast to acquired, high affinity secondary responses. In a similar manner, C3 and C4 
are displayed on opposite axes, accounting for early and later events during complement 
activation. In the resulting plot the IgM-C4 region represents classical pathway/natural 
immunity while the IgG-C3 region stands for induced immunity with AP activation. 
 
4 Perspectives 
From the technological point of view, multiplex measurements are becoming common 
practice both in research and in in vitro diagnostics. Detecting antibodies with dozens or 
more specificities with simultaneous isotype determinations are possible now using 
planar or bead arrays. Understanding the relationship between antibody binding patterns 
and biological effects in healthy and ill populations will require the standardized 
collection of data and the generation of databases on one hand. On the other hand, 
incorporation of the next step of events following antibody binding, such as complement 
activation or FcR triggering, into these datasets, could further illuminate individual 
variability and promote personalized medical interventions. 
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Figure legends 
 
Figure 1. Interactions of an IgG molecule and their effects on complement activation 
A polyclonal or oligoclonal response resulting in better epitope coverage on the target 
antigen will improve complement activation by providing C1q binding sites in close 
proximity. Epitope density on the antigen or the antigen microarray also determines the 
proximity of IgG molecules, and thereby C activation. IgG can serve as an acceptor for 
the covalent binding of C3b, promoting the generation of alternative pathway (AP) C3 
and C5 convertases. The C1 complex binds to different Ig isotypes with different 
efficiencies (IgG3>IgG1>>IgG2>>IgG4), explaining the variable classical pathway (CP) 
initiated C fixing properties of IgG subclasses. Terminal sugar moieties of the N-linked 
carbohydrate group determine MBL binding and lectin pathway (LP) activation. 
 
 
Figure 2. Scheme for complement pathway identification 
A, Matrix for identifying single pathways: by measuring the binding of three complement 
proteins (C1q, C4, C3) and using three different reaction conditions with respect to 
availability of bivalent cations, pathways contributing to C3 deposition on a particular 
feature of the array can be identified. 
B, Examples: combined activation of classical and alternative pathway by bacterial 
superantigen fusion protein pLA; alternative pathway activation by yeast extract; C3 
capture by antibodies as positive control. 
 
 Figure 3. 2D immune profiles: interpretation of C3 fixation as a function of Ig binding.  
A, On a given array different antigens appear at different positions depending on the ratio 
of IgG and C3, reflecting properties of both the antigen and immunity. The same antigen 
appears at a different position when comparing immune reactivities of different serum 
samples. B, The two approaches can be combined, giving rise to complex views of 
disease associated humoral immunity. 
 
 
Figure 4. Immune complex signatures for characterizing immune complex composition in 
populations. 
A, In order to compare the binding of different proteins to antigen arrays, a relative scale 
is used. Boxes represent interquartile ranges, whiskers stand for minimum and maximum 
values. B, To visualize 4 parameters of immune complex composition (IgM, IgG, C3, 
C4) a radar chart with four axes is used with the relative percentage scale. C and D, 
Interquartile ranges (from part a) of a given population (group 1, C; group 2, D) are 
projected onto the radar chart, resulting in patterns characterizing the given population. E, 
Areas representing different populations can be overlaid for comparison. 
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